TY - JOUR AU - Maini, R. AU - St Clair, E. W. AU - Breedveld, F. PY - 1999 DA - 1999// TI - Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial JO - Lancet. VL - 354 UR - https://doi.org/10.1016/S0140-6736(99)05246-0 DO - 10.1016/S0140-6736(99)05246-0 ID - Maini1999 ER - TY - JOUR AU - Maini, R. N. AU - Breedveld, F. C. AU - Kalden, J. R. PY - 1998 DA - 1998// TI - Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis JO - Arthritis Rheum. VL - 41 UR - https://doi.org/3.0.CO;2-W DO - 3.0.CO;2-W ID - Maini1998 ER - TY - JOUR AU - Smolen, J. S. AU - Aletaha, D. AU - Bijlsma, J. W. PY - 2010 DA - 2010// TI - Treating rheumatoid arthritis to target: recommendations of an international task force JO - Ann Rheum Dis. VL - 69 UR - https://doi.org/10.1136/ard.2009.123919 DO - 10.1136/ard.2009.123919 ID - Smolen2010 ER - TY - JOUR AU - Putrik, P. AU - Ramiro, S. AU - Kvien, T. K. PY - 2014 DA - 2014// TI - Inequities in access to biologic and synthetic DMARDs across 46 European countries JO - Ann Rheum Dis. VL - 73 UR - https://doi.org/10.1136/annrheumdis-2012-202603 DO - 10.1136/annrheumdis-2012-202603 ID - Putrik2014 ER - TY - JOUR AU - Nast, A. AU - Mrowietz, U. AU - Kragballe, K. PY - 2013 DA - 2013// TI - Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis—a multinational cross-sectional study JO - Arch Dermatol Res. VL - 305 UR - https://doi.org/10.1007/s00403-013-1372-3 DO - 10.1007/s00403-013-1372-3 ID - Nast2013 ER - TY - STD TI - World Health Organization, Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva, Switzerland: 19–23 Oct 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 25 Mar 2016. UR - http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf ID - ref6 ER - TY - JOUR AU - Dorner, T. AU - Strand, V. AU - Castaneda-Hernandez, G. PY - 2013 DA - 2013// TI - The role of biosimilars in the treatment of rheumatic diseases JO - Ann Rheum Dis. VL - 72 UR - https://doi.org/10.1136/annrheumdis-2012-202715 DO - 10.1136/annrheumdis-2012-202715 ID - Dorner2013 ER - TY - JOUR AU - Abraham, I. AU - Han, L. AU - Sun, D. PY - 2014 DA - 2014// TI - Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries JO - Future Oncol. VL - 10 UR - https://doi.org/10.2217/fon.14.43 DO - 10.2217/fon.14.43 ID - Abraham2014 ER - TY - JOUR AU - Horbrand, F. AU - Rottenkolber, D. AU - Fischaleck, J. PY - 2014 DA - 2014// TI - Erythropoietin-induced treatment costs in patients suffering from renal anemia – a comparison between biosimilar and originator drugs JO - Gesundheitswesen. VL - 76 UR - https://doi.org/10.1055/s-0033-1361111 DO - 10.1055/s-0033-1361111 ID - Horbrand2014 ER - TY - JOUR AU - Haustein, R. AU - Millas, C. AU - Höer, A. PY - 2012 DA - 2012// TI - Saving money in the European healthcare systems with biosimilars JO - GaBI J. VL - 1 UR - https://doi.org/10.5639/gabij.2012.0103-4.036 DO - 10.5639/gabij.2012.0103-4.036 ID - Haustein2012 ER - TY - JOUR AU - Lapadula, G. AU - Ferraccioli, G. F. PY - 2012 DA - 2012// TI - Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues JO - Clin Exp Rheumatol VL - 30 ID - Lapadula2012 ER - TY - STD TI - European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab). 27 Jun 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Accessed 25 Mar 2016. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf ID - ref12 ER - TY - JOUR AU - Jung, S. K. AU - Lee, K. H. AU - Jeon, J. W. PY - 2014 DA - 2014// TI - Physicochemical characterization of Remsima® JO - MAbs. VL - 6 UR - https://doi.org/10.4161/mabs.32221 DO - 10.4161/mabs.32221 ID - Jung2014 ER - TY - JOUR AU - Yoo, D. H. AU - Hrycaj, P. AU - Miranda, P. PY - 2013 DA - 2013// TI - A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study JO - Ann Rheum Dis. VL - 72 UR - https://doi.org/10.1136/annrheumdis-2012-203090 DO - 10.1136/annrheumdis-2012-203090 ID - Yoo2013 ER - TY - JOUR AU - Heijde, D. AU - Landewé, R. AU - Klareskog, L. PY - 2005 DA - 2005// TI - Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study JO - Arthritis Rheum. VL - 52 UR - https://doi.org/10.1002/art.20775 DO - 10.1002/art.20775 ID - Heijde2005 ER - TY - JOUR AU - Schiff, M. AU - Keiserman, M. AU - Codding, C. PY - 2008 DA - 2008// TI - Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate JO - Ann Rheum Dis. VL - 67 UR - https://doi.org/10.1136/ard.2007.080002 DO - 10.1136/ard.2007.080002 ID - Schiff2008 ER - TY - JOUR AU - Lipsky, P. E. AU - Heijde, D. M. AU - St Clair, E. W. PY - 2000 DA - 2000// TI - Infliximab and methotrexate in the treatment of rheumatoid arthritis JO - N Engl J Med. VL - 343 UR - https://doi.org/10.1056/NEJM200011303432202 DO - 10.1056/NEJM200011303432202 ID - Lipsky2000 ER - TY - JOUR AU - Park, W. AU - Hrycaj, P. AU - Jeka, S. PY - 2013 DA - 2013// TI - A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study JO - Ann Rheum Dis. VL - 72 UR - https://doi.org/10.1136/annrheumdis-2012-203091 DO - 10.1136/annrheumdis-2012-203091 ID - Park2013 ER - TY - JOUR AU - St Clair, E. W. AU - Heijde, D. M. AU - Smolen, J. S. PY - 2004 DA - 2004// TI - Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial JO - Arthritis Rheum. VL - 50 UR - https://doi.org/10.1002/art.20568 DO - 10.1002/art.20568 ID - St Clair2004 ER - TY - JOUR AU - Park, W. AU - Yoo, D. H. AU - Jaworski, J. PY - 2016 DA - 2016// TI - Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study JO - Arthritis Res Ther. VL - 18 UR - https://doi.org/10.1186/s13075-016-0930-4 DO - 10.1186/s13075-016-0930-4 ID - Park2016 ER - TY - JOUR AU - Blackstone, E. A. AU - Joseph, P. F. PY - 2013 DA - 2013// TI - The economics of biosimilars JO - Am Health Drug Benefits. VL - 6 ID - Blackstone2013 ER - TY - JOUR AU - Brodszky, V. AU - Baji, P. AU - Balogh, O. PY - 2014 DA - 2014// TI - Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries JO - Eur J Health Econ. VL - 15 UR - https://doi.org/10.1007/s10198-014-0595-3 DO - 10.1007/s10198-014-0595-3 ID - Brodszky2014 ER - TY - JOUR AU - Mack, A. PY - 2015 DA - 2015// TI - Norway, biosimilars in different funding systems. What works? JO - GaBI J VL - 4 UR - https://doi.org/10.5639/gabij.2015.0402.018 DO - 10.5639/gabij.2015.0402.018 ID - Mack2015 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). TNF-α inhibitors for ankylosing spondylitis and non-radiographic axial spondylarthritis. NICE technology appraisal guidance [TA383]. London: NICE; Feb 2016. https://www.nice.org.uk/guidance/ta383. Accessed 25 Mar 2016. UR - https://www.nice.org.uk/guidance/ta383 ID - ref24 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. NICE technology appraisal guidance [TA375]. London: NICE; January 2016. http://www.nice.org.uk/guidance/ta375. Accessed 25 Mar 2016. UR - http://www.nice.org.uk/guidance/ta375 ID - ref25 ER - TY - STD TI - Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016. In press. ID - ref26 ER -